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CASE REPORT
Barrett’s esophagus (BE) is a premalignant con-
dition that leads to esophageal adenocarcinoma.
The incidence of Barrett’s adenocarcinoma in
Western countries has increased dramatically over
the last three decades.1,2 Although BE and associ-
ated adenocarcinoma have been considered to be
less common in Eastern populations, recent stud-
ies have demonstrated a rising incidence of gas-
troesophageal reflux disease (GERD) and BE in
Asia.3,4 However, a corresponding increase in the
incidence of Barrett’s adenocarcinoma has not
been reported in our region.5,6 In this report, we
describe three cases who were diagnosed in a
northern city of Taiwan in order to raise awareness
of this disease entity in Taiwan.
Case Reports
Case 1
A 37-year-old man who did not smoke or drink
alcohol presented with gradual-onset dysphagia.
Three years earlier, he had undergone esopha-
gogastroduodenoscopy (EGD) at National Taiwan
University Hospital because of typical GERD symp-
toms. At that time, the squamocolumnar junction
was located 4 cm proximal to the upper ends of
the gastric mucosa and had an appearance typical
of BE (Figure 1A). A biopsy specimen proved the
presence of intestinal metaplasia. For unknown
reasons, the patient failed to receive regular endo-
scopic surveillance afterwards. The EGD performed
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3 years later showed a nodular creeping tumor of
the lower esophagus arising from the pre-existing
Barrett’s territory (Figure 1B). Pathology proved
adenocarcinoma. After multiple liver, bone and
brain metastases were identified, the patient un-
derwent intensive systemic chemotherapy with
palliative irradiation.
Case 2
A 63-year-old man with chronic GERD symptoms
for 6 months visited Taipei Medical University
Hospital with gradual-onset odynophagia of
roughly 1 month’s duration. He denied the
habits of alcohol, tobacco, and betel quid con-
sumption. EGD found a bulging tumor with cen-
tral ulceration at the lower esophagus, 33–36 cm
below the incisors (Figure 2A). The squamocolum-
nar junction was displaced 4 cm proximal to the
esophagogastric junction; velvety pink mucosa
with wave-like projections coursed across the 
ulcerated tumor. Biopsies confirmed adenocarci-
noma arising from BE. The patient was treated
with radical esophagectomy and proximal gastrec-
tomy with esophagogastric anastomosis. Exami-
nation of the surgical specimen showed that the
malignant ulcer was located near the proximal
end of the distinctive Barrett’s mucosa (Figure 2B).
Microscopically, the tumor was moderately to
poorly differentiated adenocarcinoma in glandular
structures, infiltrating as solid nests into the
desmoplastic stroma. The surrounding Barrett’s
mucosa contained intestinal metaplasia. Eight
months after surgery, the patient was free of re-
current disease, but he has since undergone two
endoscopic dilation procedures for anastomotic
stricture.
Case 3
A 44-year-old man without a history of reflux
symptoms visited National Taiwan University
Hospital because of a 6-week history of progres-
sive dysphagia and weight loss. He did not
smoke, but had limited amount of alcoholic bev-
erages. Barium swallow examination revealed an
irregular narrowing of the lower esophagus
(7 cm in length) that was continuous with the
gastroesophageal junction (Figure 3A). A sub-
sequent EGD showed an eccentric tumor of the
lower esophagus that extended longitudinally
from the gastroesophageal junction to the level
of 33 cm below the incisors. The tumor was nodu-
lar, with a friable surface (Figure 3B). The gastric
cardia was partially involved. The underlying
mucosa surrounding the tumor was composed of
pink velvety-like epithelium that extended to the
upper end of the tumor, a typical picture of BE.
Biopsies confirmed an adenocarcinoma and sur-
rounding BE (Figure 3C). Endoscopic ultrasound
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Figure 1. Case 1: (A) esophagogastroduodenoscopy reveals a proximal extension of the squamocolumnar junction
(arrow), typical of Barrett’s esophagus; (B) 3 years later, a repeat examination shows that an irregular exophyting tumor
had developed on the territory of Barrett’s mucosa.
C.H. Tu, et al
666 J Formos Med Assoc | 2007 • Vol 106 • No 8
showed that tumor depth was limited to the 
adventitia and that there was regional lymph-
adenopathy (disease stage T3N1M0). The pa-
tient was referred for concurrent cisplatin-based
chemoradiotherapy.
Discussion
This report has described three Taiwanese men of
middle to old age (range, 37–63 years) with lower
esophageal adenocarcinoma. Each of the three
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Figure 2. Case 2: (A) esophagogastroduodenoscopy shows Barrett’s mucosa appearing as a velvety pink surface with
wave-like projections coursing across the ulcerated esophageal cancer; (B) the surgical specimen shows a distinct area
between the esophagogastric junction (arrow) and the squamocolumnar junction (arrowhead), indicating Barrett’s mucosa.
The central ulcer of the tumor is within the Barrett’s territory.
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Figure 3. Case 3. (A) Barium swallow 
imaging study reveals an irregular narrowing 
at the lower esophagus that was continuous 
with the gastroesophageal junction. 
(B) Esophagogastroduodenoscopy shows an 
eccentric exophyting tumor at the lower 
esophagus. The surrounding darker mucosa is 
extended as several tongues proximal 
to the upper end of the tumor (arrow), indicating
Barrett’s esophagus. (C) Biopsy of the tumor 
margin shows malignant cells in a glandular 
pattern and necrotic debris (arrows), while 
the mucosal surface shows intestinal metaplasia
(arrowhead) (hematoxylin & eosin, 400×).
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malignant tumors was morphologically proven
to have concomitant BE. All three patients came to
medical attention only after developing symptoms
of an advanced lesion due to lack of surveillance
or adequate follow-up.
BE is an incomplete form of intestinal metapla-
sia resulting from chronic GERD, in which the
normal squamous epithelium of the esophagus is
replaced by intestinal-type epithelium. In Western
countries, it is found in approximately 6–12% of
patients with reflux symptoms who have under-
gone endoscopy. It generally affects older people,
with a peak incidence at around 55–65 years, and
has a male-to-female ratio of 7:1.7,8 Although ap-
proximately 50% of cases of esophageal adenocar-
cinoma arise from BE, reflux symptoms alone can
be associated with an increased risk. In a Swedish
study, Lagergren et al9 reported that 60% of 189
patients with esophageal adenocarcinoma had pre-
vious histories of heartburn or acid regurgitation.
Other putative risk factors include duration of
GERD symptoms, presence of nocturnal reflux
symptoms, hiatus hernia, and the absence of
Helicobacter pylori infection.10
Although a causal relationship between BE and
esophageal adenocarcinoma is well-established,
the precise mechanism of progression remains elu-
sive. It is believed that carcinogenesis may progress
through the sequence of metaplasia-dysplasia-
adenocarcinoma, with possible pathogenic roles
for repeated exposure to acid and cyclooxygenase
(COX)-2 related pathway activity.11 Chemopre-
vention with proton-pump inhibitors, COX-2 
inhibitors, and aspirin has been proposed to ar-
rest or delay progression to adenocarcinoma.12,13
However, available regimens have not convinc-
ingly decreased the likelihood of developing can-
cer. Current efforts are emphasizing endoscopic
detection of small cancer foci by using magnifi-
cation, chromoendoscopy, and/or optical devices
to identify or delineate the margin.14,15
Long-segment BE, defined as a length of intes-
tinal epithelium ≥ 3 cm, deserves intensive endo-
scopic surveillance because it is associated with
higher esophageal acid exposure and subsequent
rate of malignant transformation.16,17 In our 
report, all three patients had long-segment BE;
two of them had typical reflux symptoms. Based
on the recently validated Prague C & M criteria,18
all of their BEs can be described as C2-3 M4-7,
which confirm the clinical utility of measurement
of circumferential and maximum extents. A rela-
tively young age of onset (mean age, 48 years) in
our series deserves special attention. Liou et al19
reviewed 17,894 dyspeptic patients screened by
upper endoscopy in Taiwan and found that 13.7%
and 7.6% of patients were aged less than 45 and
40 years old, respectively. They suggested that 
40 years might be an optimal age threshold for
screening endoscopy for uninvestigated dyspepsia
in Taiwan. Our report may strengthen their find-
ings in making the optimal screening strategy
specific for Taiwanese patients with functional
gastrointestinal disorder.
We assumed that there may be an increase in
BE-associated adenocarcinoma in Taiwan, corre-
sponding to the 18.4% prevalence of endoscopic
esophagitis reported from a cross-sectional survey.4
Other supportive evidence is the 2% prevalence
of BE among a Taiwanese population of 464 self-
referred subjects, a rate that potentially matches
up with the range of rates (5–10%) reported in
Western countries.3 However, the reported inci-
dence of BE-associated adenocarcinoma may be
difficult to distinguish with cardiac gastric cancer,
especially when the tumors are disclosed in ad-
vanced stages. The misclassification can be sub-
stantial when we estimate the incidence based on
the crude database of the National Cancer Registry.
In fact, the World Health Organization classifi-
cation uses the proximal end of gastric folds to
define distal esophageal tumor, junctional tumor,
and cardiac tumor.20 El-Rifai et al21 also detected
specific genetic alterations that may be helpful in
distinguishing BE-associated adenocarcinoma
from cardiac gastric cancer. Further validation of
morphologic and histopathologic diagnoses is a
worthwhile endeavor.
In summary, we report three Taiwanese men
with advanced esophageal adenocarcinoma with
concomitant BE. In discordance to the common
thought of disease rarity in Eastern countries, these
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cases show similar characteristics to those reported
in Western countries. Although the evidence re-
mains limited, our report emphasizes the impor-
tance of risk assessment and follow-up surveillance
in patients with reflux symptoms. Updated epi-
demiologic data are therefore warranted.
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